Additionally, the shRNA targeting of RANKL in breast and prostate cancer, and shRNA targeting of IL-6 in breast cancer, resulted in smaller osteolytic lesions, reduced bone turnover, and reduced osteoclast numbers in inoculated mice. Here, IL6 is linked to prostate cancer.